NCT04203641 - L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions

Pancreas Cancer

Interventions

BIOLOGICAL

L-DOS47

A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.

DRUG

Doxorubicin

A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23

Trial Locations (3)

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale

Atlantic Health System, Morristown Medical Center, Morristown